ASH 2022 | The current state-of-the-art in MF and PV therapy and future outlooks
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, highlights recent advances made in the treatment of myelofibrosis (MF) and polycythemia vera (PV). Dr Kuykendall comments on the recent approval of novel agents and further highlights the importance of leveraging these treatments for different patient groups. To conclude, Dr Kuykendall addresses the potential role of agents such as rusfertide as an early-line therapy for PV. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Protagonist: Other: Research Support; Imago Biosciences: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy, Honoraria, Speakers Bureau; Blueprint Medicines Corporation: Consultancy, Honoraria, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; Abbvie: Consultancy, Honoraria, Speakers Bureau; GSK – Sierra Oncology: Consultancy, Honoraria, Other: Research Support, Speakers Bureau; Prelude Pharmaceuticals: Other: Research Support; BMS: Consultancy, Honoraria, Other: Research Support, Speakers Bureau; Morphosys: Other: Research Support; Pharmaessentia: Consultancy, Honoraria, Speakers Bureau; CTI Biopharma: Consultancy, Honoraria, Speakers Bureau.
